Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study - ANRS HC02

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 765-773

  Cacoub, Patrice ^a,b   Carrat, Fabrice ^a   Bédossa, Pierre ^c   Lambert, Jérôme ^a   Pénaranda, Guillaume ^d   Perronne, Christian ^e   Pol, Stanislas ^f   Halfon, Philippe ^d  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c BEAUJON HOSPITAL   (France)

^d Laboratoire Alphabio   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f AP HP Hôpital Raymond Poincaré ^*  (France)

Author keywords

Biomarkers; DANA; HCV; HIV; HIV HCV co infection; Liver biopsy; Liver fibrosis

Indexed keywords

BIOLOGICAL MARKER;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTERMETHOD COMPARISON; LABORATORY TEST; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NON INVASIVE PROCEDURE; PATIENT CODING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; VIRUS LOAD;

ADULT; BIOLOGICAL MARKERS; BIOPSY; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 40949151051     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.01.025     Document Type: Article

References (62)

1. Sulkowski M.S., and Thomas D.L. Hepatitis C in the HIV-infected person. Ann Intern Med 138 (2003) 197-207
2. Sherman K., Roustrer S., Chung R., and Rajicic N. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antivir Ther 5 (2000) 64-65
3. Benhamou Y., Bochet M., Di Martino V., Charlotte F., Azria F., Coutellier A., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 30 (1999) 1054-1058
4. Puoti M., Bonacini M., Spinetti A., Putzolu V., Govindarajan S., Zaltron S., et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 183 (2001) 134-137
5. de Torres M., and Poynard T. Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2 (2003) 5-11
6. Kramer J.R., Giordano T.P., Souchek J., Richardson P., Hwang L.Y., and El-Serag H.B. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 100 (2005) 56-63
7. Benhamou Y., Di Martino V., Bochet M., Colombet G., Thibault V., Liou A., et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34 (2001) 283-287
8. Sterling R.K., Contos M.J., Sanyal A.J., Luketic V.A., Stravitz R.T., Wilson M.S., et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 32 (2003) 30-37
9. Martin-Carbonero L., Soriano V., Valencia E., Garcia-Samaniego J., Lopez M., and Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 17 (2001) 1467-1471
10. Puoti M., Spinetti A., Ghezzi A., Donato F., Zaltron S., Putzolu V., et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 24 (2000) 211-217
11. Martin-Carbonero L., Benhamou Y., Puoti M., Berenguer J., Mallolas J., Quereda C., et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 38 (2004) 128-133
12. Cacoub P., Geffray L., Rosenthal E., Perronne C., Veyssier P., and Raguin G. Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 32 (2001) 1207-1214
13. Bica I., McGovern B., Dhar R., Stone D., McGowan K., Scheib R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 (2001) 492-497
14. Selik R.M., Byers Jr. R.H., and Dworkin M.S. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29 (2002) 378-387
15. Rosenthal E., Poiree M., Pradier C., Perronne C., Salmon-Ceron D., Geffray L., et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). Aids 17 (2003) 1803-1809
16. Rosenthal E., Pialoux G., Bernard N., Pradier C., Rey D., Bentata M., et al. Liver-related mortality in human immunodeficiency virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat 14 (2007) 183-188
17. Chung R.T., Andersen J., Volberding P., Robbins G.K., Liu T., Sherman K.E., et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 (2004) 451-459
18. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 (2004) 438-450
19. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Jama 292 (2004) 2839-2848
20. Laguno M., Murillas J., Blanco J.L., Martinez E., Miquel R., Sanchez-Tapias J.M., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. Aids 18 (2004) F27-F36
21. Fleming C.A., Craven D.E., Thornton D., Tumilty S., and Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 36 (2003) 97-100
22. Cacoub P., Rosenthal E., Halfon P., Sene D., Perronne C., and Pol S. Treatment of hepatitis C virus and human immunodeficiency virus coinfection: from large trials to real life. J Viral Hepatitis 13 (2006) 678-682
23. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 (2001) 495-500
24. McGill D.B., Rakela J., Zinsmeister A.R., and Ott B.J. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 99 (1990) 1396-1400
25. Perrault J., McGill D.B., Ott B.J., and Taylor W.F. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74 (1978) 103-106
26. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614-2618
27. Colloredo G., Guido M., Sonzogni A., and Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 39 (2003) 239-244
28. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
29. Pradat P., Alberti A., Poynard T., Esteban J.I., Weiland O., Marcellin P., et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 36 (2002) 973-977
30. Fontana R.J., and Lok A.S. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 36 (2002) S57-S64
31. Pilette C., Rousselet M.C., Bedossa P., Chappard D., Oberti F., Rifflet H., et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 28 (1998) 439-446
32. Aube C., Oberti F., Korali N., Namour M.A., Loisel D., Tanguy J.Y., et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 30 (1999) 472-478
33. Renou C., Muller P., Jouve E., Bertrand J.J., Raoult A., Benderriter T., et al. Relevance of moderate isolated thrombopenia as a strong predictive marker of cirrhosis in patients with chronic hepatitis C virus. Am J Gastroenterol 96 (2001) 1657-1659
34. Croquet V., Vuillemin E., Ternisien C., Pilette C., Oberti F., Gallois Y., et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 14 (2002) 1133-1141
35. Patel K., Lajoie A., Heaton S., Pianko S., Behling C.A., Bylund D., et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 18 (2003) 253-257
36. Xie S.B., Yao J.L., Zheng R.Q., Peng X.M., and Gao Z.L. Serum hyaluronic acid, procollagen type III and IV in histological diagnosis of liver fibrosis. Hepatobiliary Pancreat Dis Int 2 (2003) 69-72
37. Callewaert N., Van Vlierberghe H., Van Hecke A., Laroy W., Delanghe J., and Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10 (2004) 429-434
38. Patel K., Muir A.J., and McHutchison J.G. Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients. Hepatology 37 (2003) 1222
39. Oberti F., Valsesia E., Pilette C., Rousselet M.C., Bedossa P., Aube C., et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 113 (1997) 1609-1616
40. Rozario R., and Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol 38 (2003) 223-229
41. Myers R.P., Ratziu V., Imbert-Bismut F., Charlotte F., and Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 97 (2002) 2419-2425
42. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
43. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martinez-Bauer E., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36 (2002) 986-992
44. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
45. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 51 (2005) 1867-1873
46. Cales P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005) 1373-1381
47. Myers R.P., Benhamou Y., Imbert-Bismut F., Thibault V., Bochet M., Charlotte F., et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids 17 (2003) 721-725
48. Kelleher T.B., Mehta S.H., Bhaskar R., Sulkowski M., Astemborski J., Thomas D.L., et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43 (2005) 78-84
49. Sterling R.K., Lissen E., Clumeck N., Sola R., Correa M.C., Montaner J., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43 (2006) 1317-1325
50. Wilson L.E., Torbenson M., Astemborski J., Faruki H., Spoler C., Rai R., et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 43 (2006) 788-795
51. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
52. Poynard T, Halfon P, Castera L, Munteanu M, Imbert-Bismut F, Ratziu V, et al. La prévalence de chaque stade de fibrose est un facteur majeur de variabilité de l'estimation de la valeur diagnostique des marqueurs de fibrose. 60e Journées de l'AFEF, Paris September 2006.
53. Poynard T., Halfon P., Castera L., Charlotte F., Le Bail B., Munteanu M., et al. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther 25 (2007) 733-739
54. Anonymous. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA 1993;269:729-730.
55. Shire N, Rao M, Andersen J, Butt A, Chung R, Sherman K, Group. TAS. Improving Non-Invasive Discrimination of Fibrosis in HIV/HCV-co-infected Patients. 14th Conference on Retroviruses and Opportunistic Infections, 2007;#914.
56. Halfon P., Bourliere M., Penaranda G., Deydier R., Renou C., Botta-Fridlund D., et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 4 (2005) 6
57. McHutchison J.G., Blatt L.M., de Medina M., Craig J.R., Conrad A., Schiff E.R., et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 15 (2000) 945-951
58. Rivero A., Mira J.A., and Pineda J.A. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 59 (2007) 342-346
59. Lok A.S., Ghany M.G., Goodman Z.D., Wright E.C., Everson G.T., Sterling R.K., et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 42 (2005) 282-292
60. Schiano T.D., Azeem S., Bodian C.A., Bodenheimer Jr. H.C., Merati S., Thung S.N., et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 3 (2005) 930-935
61. de Ledinghen V., Douvin C., Kettaneh A., Ziol M., Roulot D., Marcellin P., et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 41 (2006) 175-179
62. Macias J., Giron-Gonzalez J.A., Gonzalez-Serrano M., Merino D., Cano P., Mira J.A., et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55 (2006) 409-414